Tetraphase Pharmaceuticals, Inc. (TTPH) Raised to Buy at Stifel Nicolaus
Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) from a hold rating to a buy rating in a research report report published on Wednesday, MarketBeat Ratings reports. The brokerage currently has $15.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $8.00.
A number of other research analysts also recently issued reports on TTPH. BMO Capital Markets reissued a buy rating and set a $12.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Friday, May 5th. Zacks Investment Research downgraded shares of Tetraphase Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, May 10th. Finally, HC Wainwright initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They set a buy rating and a $15.00 price objective on the stock. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of Buy and an average target price of $10.25.
Tetraphase Pharmaceuticals (TTPH) opened at 6.48 on Wednesday. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93. The company’s 50-day moving average is $7.45 and its 200 day moving average is $6.85. The company’s market capitalization is $245.95 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.19. The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.46 million. Tetraphase Pharmaceuticals had a negative net margin of 1,932.24% and a negative return on equity of 60.55%. The firm’s revenue for the quarter was down 24.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.46) earnings per share. On average, analysts forecast that Tetraphase Pharmaceuticals will post ($2.65) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Tetraphase Pharmaceuticals, Inc. (TTPH) Raised to Buy at Stifel Nicolaus” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/tetraphase-pharmaceuticals-inc-ttph-raised-to-buy-at-stifel-nicolaus/1462564.html.
Several hedge funds have recently made changes to their positions in TTPH. Wade G W & Inc. acquired a new stake in shares of Tetraphase Pharmaceuticals during the first quarter worth approximately $138,000. Teza Capital Management LLC boosted its stake in shares of Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,281 shares during the period. Citadel Advisors LLC boosted its stake in shares of Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 2,496 shares during the period. UBS Group AG boosted its stake in shares of Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 387 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Tetraphase Pharmaceuticals during the first quarter worth approximately $181,000. Hedge funds and other institutional investors own 46.24% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.